121 related articles for article (PubMed ID: 24925464)
1. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies.
Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464
[TBL] [Abstract][Full Text] [Related]
2. S-1 in the treatment of pancreatic cancer.
Sudo K; Nakamura K; Yamaguchi T
World J Gastroenterol; 2014 Nov; 20(41):15110-8. PubMed ID: 25386059
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
Heinemann V; Boeck S; Hinke A; Labianca R; Louvet C
BMC Cancer; 2008 Mar; 8():82. PubMed ID: 18373843
[TBL] [Abstract][Full Text] [Related]
4. Meta-analysis on resected pancreatic cancer: a comparison between adjuvant treatments and gemcitabine alone.
Chen H; He R; Shi X; Zhou M; Zhao C; Zhang H; Qin R
BMC Cancer; 2018 Oct; 18(1):1034. PubMed ID: 30352573
[TBL] [Abstract][Full Text] [Related]
5. Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for advanced pancreatic cancer.
Dalgleish AG; Stebbing J; Adamson DJ; Arif SS; Bidoli P; Chang D; Cheeseman S; Diaz-Beveridge R; Fernandez-Martos C; Glynne-Jones R; Granetto C; Massuti B; McAdam K; McDermott R; Martín AJ; Papamichael D; Pazo-Cid R; Vieitez JM; Zaniboni A; Carroll KJ; Wagle S; Gaya A; Mudan SS
Br J Cancer; 2016 Sep; 115(7):789-96. PubMed ID: 27599039
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis on inoperable pancreatic cancer: a comparison between gemcitabine-based combination therapy and gemcitabine alone.
Xie DR; Liang HL; Wang Y; Guo SS; Yang Q
World J Gastroenterol; 2006 Nov; 12(43):6973-81. PubMed ID: 17109519
[TBL] [Abstract][Full Text] [Related]
7. Nomogram to predict survival of patients with advanced and metastatic pancreatic Cancer.
Deng GC; Lv Y; Yan H; Sun DC; Qu TT; Pan YT; Han QL; Dai GH
BMC Cancer; 2021 Nov; 21(1):1227. PubMed ID: 34781928
[TBL] [Abstract][Full Text] [Related]
8. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection?
Weiss L; Heinemann V; Fischer LE; Gieseler F; Hoehler T; Mayerle J; Quietzsch D; Reinacher-Schick A; Schenk M; Seipelt G; Siveke JT; Stahl M; Vehling-Kaiser U; Waldschmidt DT; Dorman K; Zhang D; Westphalen CB; von Bergwelt-Baildon M; Boeck S; Haas M
Clin Transl Oncol; 2024 May; 26(5):1268-1272. PubMed ID: 37794220
[TBL] [Abstract][Full Text] [Related]
9. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades of the German AIO study group.
Weiss L; Fischer LE; Heinemann V; Gieseler F; Hoehler T; Mayerle J; Quietzsch D; Reinacher-Schick A; Schenk M; Seipelt G; Siveke JT; Stahl M; Kaiser U; Waldschmidt DT; Dorman K; Zhang D; Westphalen CB; Boeck S; Haas M
ESMO Open; 2024 Apr; 9(4):102944. PubMed ID: 38503144
[TBL] [Abstract][Full Text] [Related]
10. CASP1 is a target for combination therapy in pancreatic cancer.
Wang X; Chen Z; Nie D; Zeng X; Zhong M; Liu X; Zhong S; Wang L; Liao Z; Chen C; Li Y; Zeng C
Eur J Pharmacol; 2023 Dec; 961():176175. PubMed ID: 37949157
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome of advanced pancreatic cancer patients who are ineligible for a clinical trial.
Ueda A; Hosokawa A; Ogawa K; Yoshita H; Ando T; Kajiura S; Fujinami H; Kawai K; Nishikawa J; Tajiri K; Minemura M; Sugiyama T
Onco Targets Ther; 2013; 6():491-6. PubMed ID: 23690691
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study of S-1 dosing schedule for resected colorectal cancer.
Matsuda C; Uemura M; Nakata K; Shingai T; Nishimura J; Hata T; Ikenaga M; Takemasa I; Mizushima T; Kato T; Ikeda M; Ohue M; Murata K; Hasegawa J; Satoh T; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
BMC Cancer; 2015 Jun; 15():452. PubMed ID: 26036466
[TBL] [Abstract][Full Text] [Related]
13. The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Nakamura M; Yamada Y; Muro K; Takahashi K; Baba H; Sasaki Y; Komatsu Y; Satoh T; Mishima H; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Future Oncol; 2015; 11(10):1471-8. PubMed ID: 25963425
[TBL] [Abstract][Full Text] [Related]
14. Randomised phase II trial of S-1 plus oxaliplatin vs S-1 in patients with gemcitabine-refractory pancreatic cancer.
Ohkawa S; Okusaka T; Isayama H; Fukutomi A; Yamaguchi K; Ikeda M; Funakoshi A; Nagase M; Hamamoto Y; Nakamori S; Tsuchiya Y; Baba H; Ishii H; Omuro Y; Sho M; Matsumoto S; Yamada N; Yanagimoto H; Unno M; Ichikawa Y; Takahashi S; Watanabe G; Wakabayashi G; Egawa N; Tsuda M; Hosotani R; Hamada C; Hyodo I
Br J Cancer; 2015 Apr; 112(9):1428-34. PubMed ID: 25880004
[TBL] [Abstract][Full Text] [Related]
15. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naïve patients with advanced gastric cancer.
Yamada Y; Higuchi K; Nishikawa K; Gotoh M; Fuse N; Sugimoto N; Nishina T; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Hamada C; Hyodo I
Ann Oncol; 2015 Jan; 26(1):141-148. PubMed ID: 25316259
[TBL] [Abstract][Full Text] [Related]
16. Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
Mizushima T; Tamagawa H; Matsuda C; Murata K; Fukunaga M; Ota H; Hasegawa J; Tsujie M; Fukuzaki T; Hata T; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Oncology; 2015; 89(3):152-8. PubMed ID: 25967649
[TBL] [Abstract][Full Text] [Related]
17. nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: long-term survival from a phase III trial.
Goldstein D; El-Maraghi RH; Hammel P; Heinemann V; Kunzmann V; Sastre J; Scheithauer W; Siena S; Tabernero J; Teixeira L; Tortora G; Van Laethem JL; Young R; Penenberg DN; Lu B; Romano A; Von Hoff DD
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25638248
[TBL] [Abstract][Full Text] [Related]
18. Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Komatsu Y; Okita K; Yuki S; Furuhata T; Fukushima H; Masuko H; Kawamoto Y; Isobe H; Miyagishima T; Sasaki K; Nakamura M; Ohsaki Y; Nakajima J; Tateyama M; Eto K; Minami S; Yokoyama R; Iwanaga I; Shibuya H; Kudo M; Oba K; Takahashi Y
Cancer Sci; 2015 Jul; 106(7):891-5. PubMed ID: 25872578
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer.
Ryu MH; Yoo C; Kim JG; Ryoo BY; Park YS; Park SR; Han HS; Chung IJ; Song EK; Lee KH; Kang SY; Kang YK
Eur J Cancer; 2015 Mar; 51(4):482-488. PubMed ID: 25661103
[TBL] [Abstract][Full Text] [Related]
20. Phase II/III study of second-line chemotherapy comparing irinotecan-alone with S-1 plus irinotecan in advanced gastric cancer refractory to first-line treatment with S-1 (JACCRO GC-05).
Tanabe K; Fujii M; Nishikawa K; Kunisaki C; Tsuji A; Matsuhashi N; Takagane A; Ohno T; Kawase T; Kochi M; Yoshida K; Kakeji Y; Ichikawa W; Chin K; Terashima M; Takeuchi M; Nakajima T
Ann Oncol; 2015 Sep; 26(9):1916-1922. PubMed ID: 26109630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]